Literature DB >> 16942922

Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry.

James I Lee1, Mahesh Narayan, Jeffrey S Barrett.   

Abstract

A sensitive method for the simultaneous quantitation of six active constituents in commercial silymarin standardized extracts was developed based on liquid chromatography (LC) in combination with mass spectrometry (MS). The six main active constituents, namely, silydianin, silychristin, diastereoisomers of silybin (silybin A and B), and diastereoisomers of isosilybin (isosilybin A and B) were completely separated and quantified by LC/MS. Silymarin obtained from Sigma-Aldrich Co. was evaluated and used as standard reference material for the six individual constituents in comparing the relative content of silymarin and the relative ratio of each constituent in commercial standardized silymarin extracts, respectively. Significant variation was found between different commercial silymarin sources. As a result, this method has proven useful in evaluating and quantifying the six active constituents in commercial milk thistle extracts. The calibration curves were over the range from 0.25 to 100 microg/mL for silychristin and silydianin, and from 0.10 to 100 microg/mL for silybin A, silybin B, isosilybin A and isosilybin B, respectively (r(2)> or =0.9958). For all six active constituents, the overall intra-day precision values, based on the relative standard deviation replicate for four QC levels, ranged from 1.18% to 12.4% and accuracy ranged from 89.4% to 112%. This methodology could easily be incorporated into standardized testing to assess content uniformity including lot-to-lot variation as part of routine process controls as well as a means to describe cross-product variation among the exiting marketed formulations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16942922     DOI: 10.1016/j.jchromb.2006.07.063

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.318


  17 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

Review 2.  Silymarin and epithelial cancer chemoprevention: how close we are to bedside?

Authors:  Manjinder Kaur; Rajesh Agarwal
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-15       Impact factor: 4.219

3.  Magnetic Iron Oxide Nanoparticles for Biomedical Applications.

Authors:  Kaiyi Jiang; Linlin Zhang; Gang Bao
Journal:  Curr Opin Biomed Eng       Date:  2021-08-17

4.  Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells.

Authors:  G Ramakrishnan; L Lo Muzio; C M Elinos-Báez; S Jagan; T A Augustine; S Kamaraj; P Anandakumar; T Devaki
Journal:  Cell Prolif       Date:  2009-04       Impact factor: 6.831

5.  HiFSA fingerprinting applied to isomers with near-identical NMR spectra: the silybin/isosilybin case.

Authors:  José G Napolitano; David C Lankin; Tyler N Graf; J Brent Friesen; Shao-Nong Chen; James B McAlpine; Nicholas H Oberlies; Guido F Pauli
Journal:  J Org Chem       Date:  2013-03-05       Impact factor: 4.354

6.  Single Laboratory Validation of UHPLC-MS/MS Assays for Six Milk Thistle Flavonolignans in Human Serum.

Authors:  Ruth N Muchiri; Richard B van Breemen
Journal:  J AOAC Int       Date:  2021-03-05       Impact factor: 1.913

7.  Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity.

Authors:  Suvadra Das; Partha Roy; Runa Ghosh Auddy; Arup Mukherjee
Journal:  Int J Nanomedicine       Date:  2011-06-22

Review 8.  Lung Cancer Management with Silibinin: A Historical and Translational Perspective.

Authors:  Sara Verdura; Elisabet Cuyàs; Verónica Ruiz-Torres; Vicente Micol; Jorge Joven; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11

9.  Evaluation of the Cytotoxicity and Genotoxicity of Flavonolignans in Different Cellular Models.

Authors:  Michal Bijak; Ewelina Synowiec; Przemyslaw Sitarek; Tomasz Sliwiński; Joanna Saluk-Bijak
Journal:  Nutrients       Date:  2017-12-14       Impact factor: 6.706

10.  Flavonolignans Inhibit IL1-β-Induced Cross-Talk between Blood Platelets and Leukocytes.

Authors:  Michal Bijak; Angela Dziedzic; Ewelina Synowiec; Tomasz Sliwinski; Joanna Saluk-Bijak
Journal:  Nutrients       Date:  2017-09-15       Impact factor: 6.706

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.